Case number 1:22-cv-00114
Otsuka Pharmaceutical Co., Ltd. et al v. Mylan Laboratories Limited et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Mar 7, 2023 | 12 | ORDER OF DISMISSAL. This action is dismissed without prejudice and stricken from the Court's active docket. Signed by Chief District Judge Thomas S Kleeh on 3/7/2023. (jb) (Entered: 03/07/2023) (1) |
| Mar 6, 2023 | 11 | STIPULATION of Dismissal by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Higginbotham, Daniel) (Entered: 03/06/2023) (2) |
| Mar 3, 2023 | 10 | ORDER ADOPTING 114 STIPULATION FOR EXTENSION OF TIME. Signed by Chief District Judge Thomas S Kleeh on 3/3/2023. (dk) (Entered: 03/03/2023) (1) |
| Mar 2, 2023 | 9 | FIRST ORDER AND NOTICE REGARDING DISCOVERY AND SCHEDULING CONFERENCE: ***NOTICE TO ATTORNEYS*** : Pursuant to Rule 7.1 of the Federal Rules of Civil Procedure, ALL Non-governmental CORPORATE parties must file a DISCLOSURE STATEMENT with the Court. Forms are available on the Court's Web Site at http://www.wvnd.uscourts.gov/forms.htm Rule 26 Meeting to be held by 3/31/2023. Rule 26 Meeting Report due by 4/14/2023. Discovery due by 5/1/2023. Signed by Chief District Judge Thomas S Kleeh on 3/2/2023. (hrc) (Entered: 03/02/2023) (6) |
| Mar 1, 2023 | 7 | STIPULATION Extending Time to Answer or Otherwise Respond to Complaint by Mylan Pharmaceuticals Inc., Viatris Inc.. (O'Brien, William) (Entered: 03/01/2023) (2) |
| Mar 1, 2023 | 8 | NOTICE of Appearance by Brandon M. White on behalf of All Defendants (White, Brandon) (Entered: 03/01/2023) (2) |
| Nov 10, 2022 | 1 | COMPLAINT against All Defendants, filed by Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S. Filing Fee PAID $402 -. Receipt #AWVNDC-3590656. (Attachments: # 1 Exhibit A US Patent 11,400,087 B2, # 2 Civil Cover Sheet)(jmm) (Entered: 11/14/2022) (Main Document) (25) |
| Nov 10, 2022 | 2 | SUPPLEMENTAL INFORMATION FOR PATENT CASES INVOLVING AN ABBREVIATED NEW DRUG APPLICATION (ANDA) filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd. (jmm) (Entered: 11/14/2022) (1) |
| Nov 10, 2022 | 3 | Corporate Disclosure Statement by Otsuka Pharmaceutical Co., Ltd. (jmm) (Entered: 11/14/2022) (1) |
| Nov 10, 2022 | 4 | Corporate Disclosure Statement by H. Lundbeck A/S. (jmm) (Entered: 11/14/2022) (1) |
| Nov 10, 2022 | 5 | REPORT to USPTO on the filing or determination of an action regarding re 1 Complaint. (Copy Patent/Trademark Office) (jmm) (Entered: 11/14/2022) (1) |
| Nov 10, 2022 | 1 | COMPLAINT against All Defendants, filed by Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S. Filing Fee PAID $402 -. Receipt #AWVNDC-3590656. (Attachments: # 1 Exhibit A US Patent 11,400,087 B2, # 2 Civil Cover Sheet)(jmm) (Entered: 11/14/2022) (Exhibit A US Patent 11,400,087 B2) (11) |
| Nov 10, 2022 | 1 | COMPLAINT against All Defendants, filed by Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S. Filing Fee PAID $402 -. Receipt #AWVNDC-3590656. (Attachments: # 1 Exhibit A US Patent 11,400,087 B2, # 2 Civil Cover Sheet)(jmm) (Entered: 11/14/2022) (Civil Cover Sheet) (2) |
